W. H. Wilson Tang, MD

Three Days. Endless Innovation. 🚀 Dive into pioneering data and transformative innovations in #heartfailure treatment with the program guide: your ultimate resource for navigating #THT2026! ow.ly/nc2550XC4UN Not registered yet? Secure your spot and save when you register before Dec. 17.⌛ ow.ly/UKzj50XC4UQ #CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMD @javedbutler1 @preventfailure @akshaydesaimd @JerryEstepMD @FudimMarat @UlrichJordeMD @manreetkanwar @dranulala @MartyBLeon @LindenfeldJoann @SMarxLab @gtsayer @WilsonTangMD @NirUrielMD @jgranadacrf @triciarawh @TCTConference @TCTMD

How can we modify the gut microbiome to treat and prevent #HeartFailure? Great talk by @PetraMamicMD at #HFSA2025 @StanfordCVI

Annual center picture for @CleClinicCIRC ! We turn 3 years old. We’ve accomplished so much in such a short time. Feel blessed working with the many @CleClinicHVTI Staff, scientists, engineers, and students. Thanks to the support @LarsSvenssonMD @tavrkapadia @ClevelandClinic

From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding: 🔸Death/CV 🏥 🔸AF recurrence Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF 📎: jacc.org/doi/10.1016/j.… #JACCHF

Official kickoff of #THT2025 with #heartfailure innovations by @BurkhoffMd @TCTMD @HFSA

🚨 Final Call: Secure Your Discounted Room by January 22! Stay at the Omni Boston Hotel at the Seaport, the official #THT2025 venue. Rooms are limited — don’t wait! ✅ Registered attendees, use the reservation link in your confirmation email to secure your spot (subject to availability). Not registered yet? Register now to lock in your stay! tht2025.crfconferences.com/register #heartfailure #CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMD @javedbutler1 @preventfailure @akshaydesaimd @JerryEstepMD @FudimMarat @UlrichJordeMD @manreetkanwar @navinkapur4 @dranulala @MartyBLeon @LindenfeldJoann @SMarxLab @gtsayer @WilsonTangMD @NirUrielMD @jgranadacrf @triciarawh @TCTConference

@CardioNerdsJC This is in contrast with many HF trials that have resulted in neutral results, in part because many factors (cardiac or extra-cardiac) may affect pVO2 in pts with HF.

@CardioNerdsJC This is one scenario that change in pVO2 is a good choice for primary endpoint because the key determinant of pVO2 in oHCM is the obstructive physiology that is being relieved by the intervention.

Now what we all have been waiting for, the key finding: ⭐️ Mean change from baseline to week 24 in peak VO2 uptake, for aficamten vs. placebo, was: 1.8 vs. 0.0 mL/kg/min (p < 0.0001)

@ChrisKramerMD @CardioNerdsJC Wondering if it is only known LP/P sarc+ vs all got tested.

@CardioNerdsJC Fewer sarc+ patients than the average HCM clinic (35% or so) but obstruction is more common in Sarc- pts

Is this a representative HCM population? Specially looking at: 🌎 79% White patient representation 🧬17.5% with pathogenic sarcomeric variant 💊Prevalence of BB, CCB, disopyramide use 🫀NYHA Class ratio #CardsJC

🆕statement on evaluating & managing kidney dysfunction in patients with advanced heart failure. 📷Approach to assessment of kidney dysfunction in advanced HF ✍🏼@nishakidneydoc @WilsonTangMD @RangaswJ @FiedlerAmy @modeldoc @PietermartensMD @JamesCFangMD @CunningBeans @mbakitas

@JeroenDauw @WilfriedMullens @FH_Verbrugge @piet_stinissen @pietvandervoort @ECraenenbroeck Congrats!

Last Wednesday I successfully defended my PhD ‘Unravelling congestion in heart failure: mechanisms, diagnosis and treatment’. Special thanks to my promotor @WilfriedMullens, my family, the exquisite members of the jury and all people who helped me throughout my journey!

#Perspective: Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases @CCLRI @WilsonTangMD ahajournals.org/doi/10.1161/CI…

Acetazolamide prevents loop diuretic resistance. #THT2024 @WilfriedMullens @WilsonTangMD

Great start with our fearless leader @BurkhoffMd kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites nature.com/articles/s4159… @NatureMedicine

The new #JACCHF issue is now out! Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. bit.ly/49p3hjk #CHF @WilsonTangMD

So incredibly proud of @ClevelandClinic representation at #CMR2024 in London @SCMRorg. 14 oral presentations and a ECA finalist. Celebrating at last night’s dinner! @ATandonMD @DebbieKwonMD @CleClinicCIRC @CleClinicHVTI @CleClinicLCM

The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic! Read about his work below. myocarditisfoundation.org/the-myocarditi…

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency? A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations. bit.ly/4aL4MKs #JACCHF

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. bit.ly/3N5qfU4 @CVCTForum @PieterMartensMD @WilsonTangMD